SCHEDULE 13D/A: RA Capital Increases Stake in Solid Biosciences to 9.9% Through Pre-Funded Warrant Purchase

RA Capital Management and its affiliates have increased their beneficial ownership in Solid Biosciences Inc. to 9.9% following the purchase of pre-funded warrants for approximately $15 million.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed Amendment No. 9 to their Schedule 13D.
• The Reporting Persons collectively beneficially own 7,989,820 shares of Solid Biosciences Inc. common stock, representing 9.9% of the class.
• RA Capital Healthcare Fund, L.P. specifically beneficially owns 7,823,558 shares, representing 9.8% of the class.
• On February 19, 2025, RA Capital Healthcare Fund, L.P. purchased Pre-Funded Warrants to acquire up to 3,722,085 shares of common stock at a price of $4.029 per share from the underwriters of Solid Biosciences' 2025 public offering.
• The aggregate purchase price for these pre-funded warrants was $14,996,280, funded by the working capital of RA Capital Healthcare Fund, L.P.
• The beneficial ownership includes shares directly held by RA Capital Healthcare Fund, L.P. (4,192,216 shares), RA Capital Nexus Fund, L.P. (109,661 shares), a separately managed account (28,569 shares), vested stock options held by Mr. Shah (28,032 shares), and the newly acquired pre-funded warrants (exercisable for up to 3,722,085 shares).
• The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable, and do not expire.
• A 'Beneficial Ownership Blocker' provision in the warrants prevents exercise if it would cause the Fund's beneficial ownership to exceed 9.99% of outstanding common stock, though this percentage can be increased to 19.99% with 61 days' notice.
• The percentage of class represented is based on 76,318,810 shares of common stock outstanding after the 2025 Offering, plus shares from Mr. Shah's options and exercisable pre-funded warrants.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. An established investment firm increasing its stake, particularly through a significant purchase of pre-funded warrants, can be interpreted as a vote of confidence in the company's future, despite the filing being a factual disclosure.

Positives

• A significant investment firm, RA Capital, has increased its stake in Solid Biosciences, potentially signaling confidence in the company's future prospects.
• The acquisition of pre-funded warrants provides RA Capital with a flexible mechanism to increase its ownership without immediately exceeding a certain beneficial ownership threshold, while retaining the right to do so in the future.

Risks

• The 'Beneficial Ownership Blocker' limits the immediate exercise of pre-funded warrants to prevent the Fund from exceeding 9.99% beneficial ownership, which could restrict the Fund's ability to fully capitalize on its investment or exert greater influence without prior notice.
• The ability to increase the beneficial ownership limit to 19.99% requires 61 days' notice to the Issuer, introducing a potential delay in increasing control or stake.

Future Outlook

The document primarily reports a change in beneficial ownership and does not contain explicit forward-looking statements or guidance from the Issuer or the Reporting Persons regarding future business operations or financial performance, beyond the terms of the pre-funded warrants allowing for potential future exercise.

Industry Context

This filing indicates continued investment by a specialized healthcare fund in a biotechnology company, Solid Biosciences Inc., which operates in a capital-intensive industry often reliant on public offerings for funding. The acquisition of pre-funded warrants is a common investment vehicle in the biotech sector, allowing investors to participate in offerings while managing ownership thresholds.

Stakeholder Impact

• **Shareholders**: The increased stake by RA Capital, a prominent healthcare investor, could be viewed positively, potentially signaling institutional confidence and stability. It also indicates a significant shareholder with a substantial interest in the company's performance.
• **Company Management**: The investment provides additional capital to Solid Biosciences Inc. (via the 2025 Offering) and aligns interests with a major institutional investor, potentially influencing strategic decisions or providing support.

Next Steps

• RA Capital Healthcare Fund, L.P. may elect to increase its beneficial ownership limit from 9.99% to 19.99% by providing 61 days' notice to Solid Biosciences Inc.
• The Pre-Funded Warrants are immediately exercisable, allowing the Fund to convert them into common stock at any time, subject to the beneficial ownership blocker.

Key Dates

Keywords

RA Capital Management, Solid Biosciences Inc., Schedule 13D/A, Beneficial Ownership, Pre-Funded Warrants, Public Offering, Investment, Biotechnology, Healthcare Fund, SEC Filing